Independent urology faces stagnant Medicare pay, rising costs, prior auth burden, and consolidation pressure, Celeste Kirschner, CAE, MHSA, says.
|Articles|July 1, 2003
Reform of policy on cancer drug pay gains momentum
Author(s)Bob Gatty
Washington-As Congress moves toward possible approval of a new prescriptiondrug program for Medicare recipients later this summer, determination ofpayments for cancer drugs and therapeutic services may well hang in thebalance.
Advertisement
Advertisement
Related to this article
LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation.
Advertisement
Advertisement
Trending on Urology Times
1
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
2
Topical sildenafil cream associated with lower systemic exposure vs oral sildenafil
3
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
4
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
5